



## CO-FOUNDER NEEDED

# De Novo Design of Cancer Immunotherapy

## PARALLAX BIO

### THE PROBLEM

Targeting cancer cells specifically with the immune system is challenging and lengthy

### OUR SOLUTION

We have set up a pipeline to design, validate, and refine minibinders (miBs) that potentially and specifically target these intracellular cancer antigens. Our computational platform enables the rapid de novo design of ideal binders, which can then be utilised in flexible therapeutic formats, such as CAR-T cells and T-cell engagers.

### PATENT STATUS

We have filed a provisional patent application (P71 51 EP00) that covers our core platform technology and the composition of matter for 39 validated miBs targeting the NY-ESO-1 antigen.

### FINANCIAL OVERVIEW

Our strategy is to validate our platform by developing assets for initial oncology indications, such as NY-ESO-1 + sarcomas, and then secure partnerships with larger biotech and pharmaceutical companies to expand into broader therapeutic areas like autoimmunity. The global immunotherapy market is projected to reach \$274B by 2030, and our focus on next-generation cell therapies addresses a rapidly growing segment within that market. We have secured several multiyear grants (~12M DKK) for projects revolving around the concept and are currently seeking €1.5M to advance our lead candidate and expand the platform.

### MILESTONES ACHIEVED

**Proof-of-Concept:** Successfully designed, validated, and specificity-engineered a miBd against the NY-ESO-1 tumour antigen, achieving a 6.8 nM affinity.

**Potent Killing:** Demonstrated that CAR-T cells equipped with our miBd can potently and specifically kill cancer cells *in vitro*.

**Business Development:** Gained early traction and interest from life science investors.

### TARGET MARKET & CUSTOMERS

Our primary customers are biotechnology and pharmaceutical companies for co-development and licensing partnerships. Our initial target market is oncology, with a focus on orphan indications such as synovial sarcoma and other cancers that express NY-ESO-1 and PRAME.



PARALLAX  
Bio

### CO-FOUNDER PROFILE WE ARE LOOKING FOR

#### Must-have qualifications/background

- Experienced biotech Business developer (potentially with experience in establishing strategic partnerships and negotiating licensing deals with pharmaceutical companies).
- Direct experience in the cell therapy market, protein design, or immunotherapeutics, particularly with CAR-T or TCR-based therapeutics.

#### Nice-to-have qualifications/background

- Demonstrated success in fundraising, including preparing data rooms and leading investor outreach for Series A or later rounds.
- Experience guiding clinical strategy and engaging with regulatory bodies (EMA/FDA).
- An existing network of contacts within top-tier venture capital firms and major pharmaceutical companies.
- Experience with the manufacturing and CMC aspects of biologic drugs, including managing CDMO relationships.

#### Personal fit

We are seeking a business development professional who can effectively translate our breakthrough science into a compelling commercial strategy. The ideal candidate will be a collaborative partner to the scientific founders, able to thrive in a fast-paced, milestone-driven startup environment. They must possess excellent communication skills to articulate our value proposition to investors, partners, and future team members. A willingness to be present in the Copenhagen area is strongly preferred to foster a cohesive team culture.

#### TASKS & RESPONSIBILITIES (FIRST 3 MONTHS)

- The primary challenge is to establish a robust corporate and strategic framework around our science to prepare for a Series A funding round.
- Lead business development activities by initiating contact with potential biotech partners.
- Drive the fundraising strategy by finalising Series A data room and beginning investor outreach.
- Formalise the company's governance by helping to establish the board and recruit scientific advisors.


#### ACADEMIC & ENTREPRENEURIAL BACKGROUND OF CURRENT CO-FOUNDERS

Our founding team consists of leading academics with deep expertise in immunology and computational protein design:

Sine Reker Hadrup (Professor) is a leading expert in T-cell Immunology who has cofounded 3 startups (PokeAcCell, Tetramer Shop, and Nano-X). Timothy P. Jenkins (Assoc. Professor) is expert in Computational Protein Design and BioAI and has cofounded 2 startups (AffinityAI and AVA XR). Kristoffer H. Johansen (Asst. Professor) is expert in immune cell engineering and has been involved in two early startup projects (Immunité, Clickflow Medtech).

#### PHYSICAL ADDRESS

DTU Healthtech,  
2800 Kgs. Lyngby



### ABOUT OPEN ENTREPRENEURSHIP

Open Entrepreneurship is a collaboration between all Danish universities aiming to create more research-based startups.

[www.open-entrepreneurship.com](http://www.open-entrepreneurship.com)



SUPPORTED BY

Uddannelses- og  
Forskningsministeriet